Comparative Pharmacology
Head-to-head clinical analysis: INLYTA versus PONATINIB HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INLYTA versus PONATINIB HYDROCHLORIDE.
INLYTA vs PONATINIB HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are involved in pathologic angiogenesis, tumor growth, and metastatic progression of cancer.
Ponatinib is a potent oral tyrosine kinase inhibitor that inhibits BCR-ABL, including T315I mutant, as well as VEGFR, PDGFR, FGFR, and SRC kinases.
5 mg orally twice daily, approximately 12 hours apart, with or without food.
45 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 13–17 hours in patients, supporting twice-daily dosing.
Terminal half-life of approximately 29 hours (range 18–48 h) supporting once-daily dosing; steady-state reached within 7 days.
Primarily hepatic metabolism via CYP3A4 and subsequent biliary-fecal elimination (approximately 61% of dose recovered in feces, 23% in urine as metabolites; <10% excreted unchanged in urine or feces).
Primarily hepatobiliary excretion; ~87% of dose recovered in feces (mostly as metabolites), <5% in urine as unchanged drug.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor